Iovance Biotherapeutics argues that there is a meaningful opportunity here of more than 8,000 patients diagnosed annually in ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...

Focused on infectious disease therapies, this biotech firm reported a notable insider sale amid a year of strong share price ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

Now, it’s worth noting Stock Advisor’s total average return is 930 % — a market-crushing outperformance compared to 185% for ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector's two major indexes - the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) - ...

As a result, since the start of the year, two formerly down-and-out stocks in these industries are outperforming the S&P 500.

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Fund started the year optimistically, expecting fiscal and ...